Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy

BACKGROUND: Cancer immunotherapy has evolved from interferon-alpha (IFNα) and interleukin-2 in the 1980s to CTLA-4 and PD-1/PD-L1 checkpoint inhibitors (CPIs), the latter highlighting the importance of enhancing T-cell functions. While the search for novel immunomodulatory pathways continues, combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cubas, Rafael, Khan, Zia, Gong, Qian, Moskalenko, Marina, Xiong, Huizhong, Ou, Qinglin, Pai, Christine, Rodriguez, Ryan, Cheung, Jeanne, Chan, Andrew C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604869/
https://www.ncbi.nlm.nih.gov/pubmed/33127657
http://dx.doi.org/10.1136/jitc-2020-001439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604869/
https://www.ncbi.nlm.nih.gov/pubmed/33127657
http://dx.doi.org/10.1136/jitc-2020-001439

Ejemplares similares